Research has shed light on how a new type of antibody treatment reactivates patients' immune cells to fight ovarian cancer.

A phase 1 open-label trial is underway, evaluating the safety and efficacy of CT-95 in patients with mesothelin-expressing ...

The first patient has been dosed in a phase 1 clinical trial of CT-95 among patients with mesothelin-expressing solid tumors.

The SB221 trial was structured to evaluate the combination’s tolerability, pharmacodynamics, safety and pharmacokinetics.

Antibody-drug conjugates and their development remains a central theme in ongoing research within the realm of ovarian cancer ...

AstraZeneca has been busy in recent years pumping up its oncology pipeline via a shopping list of assets and companies. | ...

A new case report was published in Oncoscience's Volume 12 on March 31, 2025, titled "Cystadenofibroma and contralateral collision lesions: A unique ovarian case report." ...

CT-95 is a mesothelin x CD3 T cell engaging bispecific antibody CT-95 is Context’s second T cell engaging bispecific antibody to enter the clinic ...

Results from a new Phase 3 trial published in the journal npj Precision Oncology found that an assay that includes an ...

The firm previously said it will test the CER T-cell therapy CER-1236 in blood cancers after receiving FDA manufacturing clearance.